Predictors of Unfavorable Outcomes in Patients with Atrial Fibrillation and Concomitant Heart Failure with Different Ejection Fractions: RIF-CHF Register One-Year Follow-Up

Table 4

Medications for AF and CHF in studied groups.

Parameters	Total cohort ()	AF-HFpEF ()	AF-HFmEF EF ()	AF-HFrEF ()	level
Treatment strategy for AF
Rhythm control	339 (33.8%)	157 (40.6%)	52 (34.7%)	130 (27.9%)	<0.001
Rate control	664 (66.2%)	230 (59.4%)	98 (65.3%)	336 (72.1%)
Rational therapy of CHF	396 (39.5%)	106 (27.4%)	78 (52%)	212 (45.5%)	<0.001
Beta-blocker	830 (82.8%)	301 (77.8%)	136 (90.7%)	393 (84.3%)	<0.001
Antiarrhythmic	255 (25.4%)	123 (31.8%)	37 (24.7%)	95 (20.4%)	<0.001
RAS antagonist	218 (21.7%)	116 (30%)	27 (18%)	75 (16.1%)	<0.001
Aldosterone blocker	642 (64%)	164 (42.4%)	116 (77.3%)	362 (77.7%)	<0.001
Statin	606 (60.4%)	252 (65.1%)	89 (59.3%)	265 (56.9%)	0.046
Diuretic	883 (88%)	332 (85.8%)	131 (87.3%)	420 (90.1%)	0.137
Digoxin	360 (35.9%)	101 (26.1%)	53 (35.3%)	206 (44.2%)	<0.001
Oral anticoagulant (warfarin or/and NOAC)	688 (68.6%)	274 (70.8%)	119 (79.3%)	295 (63.3%)	<0.001
Warfarin	403 (40.2%)	157 (40.6%)	66 (44%)	180 (38.6%)	0.491
NOAC	335 (33.4%)	140 (36.2%)	55 (36.7%)	140 (30%)	0.107
Oral antiplatelet, total	466 (46.5%)	177 (45.7%)	61 (40.7%)	228 (48.9%)	0.200